Diamyd Medical AB is dedicated to find a cure for type 1 diabetes: first, the autoimmune inflammation need to be down-regulated with a compound such as for example GABA; second, tolerance need to be induced to insulin producing beta cell auto-antigens such as for example GAD65; third, the beta cell mass need to be restored with for example autologous stem cells. Diamyd is actively working on all these three steps. Additionally it helps with the development of technological means to simplify the life for individuals with diabetes.

Product portfolio

A GABA compound for down-regulation of inflammation. Gliadin an antigen in celiac disease. Diamyd, a (GAD65 based, type 1 diabetes vaccine). Injections with GAD65, an autoantigen involved in type 1 diabetes, has in European phase III trials showed a 16% efficacy (p=0.1) in delaying the destruction of beta cells.